Johnson & Johnson (NYSE:JNJ) is Saratoga Research & Investment Management's 10th Largest Position

Saratoga Research & Investment Management decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 532,439 shares of the company's stock after selling 19,314 shares during the quarter. Johnson & Johnson comprises about 3.8% of Saratoga Research & Investment Management's portfolio, making the stock its 10th biggest holding. Saratoga Research & Investment Management's holdings in Johnson & Johnson were worth $86,287,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Anchor Investment Management LLC grew its holdings in Johnson & Johnson by 2.0% in the 3rd quarter. Anchor Investment Management LLC now owns 90,873 shares of the company's stock valued at $14,727,000 after buying an additional 1,761 shares in the last quarter. Tudor Financial Inc. purchased a new position in Johnson & Johnson during the third quarter worth about $888,000. Te Ahumairangi Investment Management Ltd grew its stake in shares of Johnson & Johnson by 10.1% in the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 50,765 shares of the company's stock valued at $8,180,000 after buying an additional 4,640 shares during the period. Passumpsic Savings Bank acquired a new stake in shares of Johnson & Johnson during the 3rd quarter worth approximately $262,000. Finally, McIlrath & Eck LLC lifted its holdings in Johnson & Johnson by 10.7% in the third quarter. McIlrath & Eck LLC now owns 2,892 shares of the company's stock valued at $469,000 after acquiring an additional 279 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have commented on JNJ. Royal Bank of Canada lifted their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an "outperform" rating in a research report on Wednesday, October 16th. Bank of America restated a "neutral" rating and issued a $166.00 price objective on shares of Johnson & Johnson in a report on Tuesday. Cantor Fitzgerald restated an "overweight" rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 16th. StockNews.com upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research note on Saturday, September 14th. Finally, Morgan Stanley increased their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 16th. Seven research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Johnson & Johnson has an average rating of "Moderate Buy" and an average target price of $174.73.

Johnson & Johnson Stock Performance

Shares of JNJ traded down $0.40 during mid-day trading on Thursday, hitting $146.24. 6,125,889 shares of the company's stock were exchanged, compared to its average volume of 7,118,491. The business's 50 day moving average is $157.29 and its two-hundred day moving average is $156.35. Johnson & Johnson has a fifty-two week low of $143.13 and a fifty-two week high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $352.09 billion, a P/E ratio of 21.28, a P/E/G ratio of 2.66 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same period in the previous year, the firm earned $2.66 EPS. The business's revenue for the quarter was up 5.2% compared to the same quarter last year. On average, equities analysts expect that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.39%. The ex-dividend date of this dividend was Tuesday, November 26th. Johnson & Johnson's dividend payout ratio is currently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.